NASDAQ:COLL • US19459J1043
View the latest analyst price targets, stock forecast, EPS estimates, revenue projections, revisions, full estimates, rating distribution and upgrades/downgrades for COLLEGIUM PHARMACEUTICAL INC (COLL).
| Date | Firm | Action | From → To |
|---|---|---|---|
| 2026-03-20 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2026-03-19 | Needham | Reiterate | Buy -> Buy |
| 2026-02-26 | Needham | Maintains | Buy -> Buy |
| 2026-01-09 | Barclays | Maintains | Overweight -> Overweight |
| 2026-01-09 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2026-01-08 | Needham | Maintains | Buy -> Buy |
| 2025-12-09 | Barclays | Initiate | Overweight |
| 2025-11-07 | Truist Securities | Maintains | Buy -> Buy |
| 2025-11-07 | HC Wainwright & Co. | Maintains | Buy -> Buy |
| 2025-10-28 | Needham | Reiterate | Buy -> Buy |
| 2025-05-09 | Piper Sandler | Reiterate | Neutral -> Neutral |
| 2025-04-09 | Needham | Reiterate | Buy -> Buy |
| 2025-03-24 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2025-02-04 | Piper Sandler | Maintains | Neutral -> Neutral |
| 2025-01-10 | Needham | Upgrade | Hold -> Buy |
| 2025-01-10 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2024-10-11 | Piper Sandler | Reiterate | Neutral -> Neutral |
| 2024-09-05 | HC Wainwright & Co. | Maintains | Buy -> Buy |
| 2024-08-09 | Needham | Reiterate | Hold |
| 2024-08-09 | Truist Securities | Maintains | Buy -> Buy |
| 2024-08-09 | Piper Sandler | Reiterate | Neutral -> Neutral |
| 2024-07-30 | Needham | Reiterate | Hold |
| 2024-07-30 | HC Wainwright & Co. | Upgrade | Neutral -> Buy |
| 2024-06-07 | Jefferies | Upgrade | Hold -> Buy |
| 2024-05-10 | Needham | Downgrade | Buy -> Hold |
| 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY % growth | 566.767M 22.17% | 631.449M 11.41% | 780.567M 23.62% | 843.09M 8.01% | 802.28M -4.84% | 791.81M -1.31% | 814.13M 2.82% | 849.25M 4.31% | 853.54M 0.51% | 573.75M -32.78% | |
| EBITDA YoY % growth | 324.717M 59.49% | 339.055M 4.42% | 405.71M 19.66% | 458.31M 12.96% | 424.06M -7.47% | 452.83M 6.78% | 428.2M -5.44% | 451.76M 5.50% | N/A | N/A | |
| EBIT YoY % growth | 175.461M 152.83% | 169.895M -3.17% | 179.636M 5.73% | 374M 108.20% | 282.77M -24.39% | 311.1M 10.02% | 409.68M 31.69% | 430.54M 5.09% | N/A | N/A | |
| Operating Margin | 30.96% | 26.91% | 23.01% | 44.36% | 35.25% | 39.29% | 50.32% | 50.70% | N/A | N/A | |
| EPS YoY % growth | 1.18 110.71% | 6.45 446.61% | 7.46 15.66% | 7.44 -0.28% | 6.52 -12.41% | 5.95 -8.68% | 6.24 4.91% | 6.61 5.88% | N/A | N/A |
All data in USD
| Q1 / 26 | Q2 / 26 | Q3 / 26 | Q4 / 26 | Q1 / 27 | Q2 / 27 | Q3 / 27 | Q4 / 27 | |
|---|---|---|---|---|---|---|---|---|
| EPS Q2Q % growth | 1.66 11.47% | 1.78 6.15% | 1.96 -12.92% | 2.06 1.08% | 1.43 -13.94% | 1.58 -11.31% | 1.77 -9.76% | 1.84 -10.57% |
| Revenue Q2Q % growth | 191.11M 7.51% | 201.33M 7.09% | 223.53M 6.77% | 230.71M 12.30% | 189.14M -1.03% | 198.05M -1.63% | 204.3M -8.60% | 211.71M -8.24% |
| EBITDA Q2Q % growth | 105.95M 35.40% | 110.83M -25.25% | 128.76M -44.44% | 129.48M -54.86% | 122.34M 15.47% | 129.21M 16.58% | 134.79M 4.68% | 139.69M 7.89% |
| EBIT Q2Q % growth | 83.669M 285.80% | 91.664M 161.11% | 100.99M 62.66% | 107.25M 76.52% | 62.004M -25.89% | 66.388M -27.57% | 70.535M -30.16% | 73.984M -31.02% |
All data in USD
12 analysts have analysed COLL and the average price target is 55.25 USD. This implies a price increase of 58.17% is expected in the next year compared to the current price of 34.93.
COLLEGIUM PHARMACEUTICAL INC (COLL) will report earnings on 2026-05-07.
The consensus EPS estimate for the next earnings of COLLEGIUM PHARMACEUTICAL INC (COLL) is 1.66 USD and the consensus revenue estimate is 191.11M USD.
The expected long term growth rate for COLLEGIUM PHARMACEUTICAL INC (COLL) is -0.21%.